Summary
June 2007, Vol. 2, No. 6, Pages 889-903 , DOI 10.1517/17460441.2.6.889

Use of RNA in drug design

Irene M Lagoja PhD & Piet Herdewijn PhD
Katholieke Universiteit Leuven, Laboratory of Medicinal Chemistry, Rega Institute for Medical Research, Minderbroedersstraat 10, B-3000 Leuven, Belgium +32 16 337396; +32 16 337340;
Author for correspondence



This is a review of RNA as a target for small molecules (ribosomes, riboswitches, regulatory RNAs) and RNA-derived oligonucleotides as tools (antisense/small interfering RNA, ribozymes, aptamers/decoy RNA and microRNA). This review highlights the present state of research using RNA as a drug target or as a potential drug candidate and explains at which stage and to what extent rational design could eventually be involved. Special attention has been paid to the recent potential clinical applications of RNA either as drugs or drug targets. The review deals mainly with mechanistic approaches rather than with physicochemical or computational aspects of RNA-based drug design.

Full Text | PDF (463 KB) | PDF Plus (697 KB)

Forward Links to Citing Articles

Donavon C Hiss, Gary A Gabriels. Implications of endoplasmic reticulum stress, the unfolded protein response and apoptosis for molecular cancer therapy. Part II: targeting cell cycle events, caspases, NF-κB and the proteasome. Expert Opinion on Drug Discovery 0:0,
Summary | Full Text | PDF (341 KB) | PDF Plus (342 KB) 
 

Prev. Article | Next Article
View/Print PDF (463 KB)
View PDF Plus (697 KB)
Add to favourite
Email to a friend
TOC Alert | Citation Alert What is RSS?

 
 
Quick Search
for 
Authors:
Irene M Lagoja
Piet Herdewijn
Keywords:
antisense
aptamers/decoy RNA
miRNA, regulatory RNA
ribosomes, riboswitches
ribozymes
siRNA